FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin’s lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation-Reference-Cited by-同舟云学术

FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin’s lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation

Published:2009-02 Issue:2 Volume:82 Page:143-147
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Nishio Mitsufumi,Endo Tomoyuki,Fujimoto Katsuya,Yamamoto Satoshi,Obara Masato,Yamaguchi Keisuke,Takeda Yukari,Goto Hideki,Kasahara Ikumi,Sato Norihiro,Koike Takao

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2008.01174.x/fullpdf

Reference22 articles.

1. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy;Czuczman;J Clin Oncol,1999

2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol,1998

3. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin’s lymphoma;Shortt;Bone Marrow Transplant,2006

4. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin’s lymphoma;Shimoni;Br J Haematol,2003

5. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma;Horwitz;Blood,2004

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors;Clinical Cancer Research;2023-12-13

2. Flow cytometry for B-cell subset analysis in immunodeficiencies;Journal of Immunological Methods;2022-10

3. Secondary rituximab‐associated versus primary immunodeficiencies: The enigmatic border;European Journal of Immunology;2022-08-10

4. Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs;Hematology;2020-12-04

5. The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis;Neurotherapeutics;2020-10